Literature DB >> 7532211

The 84-kDa form of human matrix metalloproteinase-9 degrades substance P and gelatin.

J R Backstrom1, Z A Tökés.   

Abstract

Matrix metalloproteinase-9 (MMP-9) is secreted from cells and, once activated, is thought to degrade collagen in the extracellular matrix. Because collagen is not readily localized where neurons have been shown to produce MMP-9 in the human brain, the ability of this enzyme to degrade bioactive peptides was investigated with representative tachykinin peptides [substance P (SP), neurokinin A, neurokinin B, and kassinin]. Latent MMP-9 (94 kDa) was purified from the human cell line HL-60 and converted to an intermediary active form (84 kDa) with p-aminophenylmercuric acetate. This active form of MMP-9 degraded SP with a kcat/Km of 170 mM-1 min-1, which is 30-fold greater than the previously reported value for a representative collagen-derived peptide. The major digestion products were identified as SP and SP, which were derived from cleavage of the Gln6-Phe7 bond. Minor products were also generated from cleavage of the Gly9-Leu10 bond. The other representative tachykinin peptides were cleaved at rates > 10-fold slower than that of SP. The 84-kDa peptidase was also active as a gelatinase. Longer treatment of MMP-9 with p-aminophenylmercuric acetate caused the conversion of the 84-kDa enzyme to the established 68-kDa active form; however, the rate of SP degradation did not increase. Because MMP-9 is produced by neurons of the CNS, these results suggest a possible regulatory role for the enzyme in interacellular communication by altering the availability of bioactive peptides.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7532211     DOI: 10.1046/j.1471-4159.1995.64031312.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  16 in total

1.  Investigation of the metabolism of substance P at the blood-brain barrier using LC-MS/MS.

Authors:  Arvind K Chappa; Joshua D Cooper; Kenneth L Audus; Susan M Lunte
Journal:  J Pharm Biomed Anal       Date:  2006-11-21       Impact factor: 3.935

2.  Matrix metalloproteinase 9 is a distal-less 3 target-gene in placental trophoblast cells.

Authors:  Patricia A Clark; Jianjun Xie; Sha Li; Xuesen Zhang; Scott Coonrod; Mark S Roberson
Journal:  Am J Physiol Cell Physiol       Date:  2013-05-08       Impact factor: 4.249

3.  Constriction of carotid arteries by urokinase-type plasminogen activator requires catalytic activity and is independent of NH(2)-terminal domains.

Authors:  Philip G Massey; Shinji Tanaka; Joshua M Buckler; Bo Jiang; Anton McCourtie; Kun Qian; Clifford Tom; April Stempien-Otero; Shan Wen; Ian Luttrell; Kanchan Chitaley; David A Dichek
Journal:  Thromb Haemost       Date:  2009-11       Impact factor: 5.249

4.  Increased expression of CD147 and MMP-9 is correlated with poor prognosis of salivary duct carcinoma.

Authors:  Songlin Piao; Shu Zhao; Fulin Guo; Jie Xue; Guodong Yao; Zhili Wei; Qi Huang; Yao Sun; Bin Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-04       Impact factor: 4.553

5.  Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40).

Authors:  J R Backstrom; G P Lim; M J Cullen; Z A Tökés
Journal:  J Neurosci       Date:  1996-12-15       Impact factor: 6.167

6.  Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma.

Authors:  Zhen Liu; Lixia Li; Zhixiong Yang; Weiren Luo; Xin Li; Huiling Yang; Kaitai Yao; Bin Wu; Weiyi Fang
Journal:  BMC Cancer       Date:  2010-06-09       Impact factor: 4.430

7.  Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth.

Authors:  Marten Falkenberg; Clifford Tom; Mary Beth DeYoung; Shan Wen; Ruth Linnemann; David A Dichek
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

Review 8.  MMP induction and inhibition in myocardial infarction.

Authors:  Merry L Lindsey
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

9.  Inverse correlation between Naa10p and MMP-9 expression and the combined prognostic value in breast cancer patients.

Authors:  Yan Zeng; Caiyun Liu; Bin Dong; Yuanyuan Li; Beihai Jiang; Ye Xu; Lin Meng; Jian Wu; Like Qu; Chengchao Shou
Journal:  Med Oncol       Date:  2013-04-02       Impact factor: 3.064

10.  Correlation of TNFAIP8 overexpression with the proliferation, metastasis, and disease-free survival in endometrial cancer.

Authors:  Tianbo Liu; Hongyu Gao; Meng Yang; Tingting Zhao; Yunduo Liu; Ge Lou
Journal:  Tumour Biol       Date:  2014-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.